A large group photo of people with FA and their families in London 13/10/26

An open letter to Christopher A. Viehbacher, CEO of Biogen.

I’m not a public figure, I don’t write open letters. But this time, something is happening in the tiny part of our world in which I have some knowledge of and may have a little influence over. Since 2019, I have blogged about the development, troubled release and most recently, the impact of this struggle on our community of Skyclarys – the first effective treatment for my condition. The problem is that despite being easily available in other countries, the drug remains unavailable to the estimated 1100 people in the UK who could benefit from it. There is an impasse, the elephant-in-the-room is the eyewatering cost. Here is my letter to Christopher A Viehbacher, CEO of Biogen urging him to reconsider the price of Skyclarys. If I receive a reply, I will post it below.

*update 8/11/26- I received a reply by email (below) on 4/11/26 from Biogen’s Medical Information Team. Although it is contains nothing new, the quick turnaround shows that this is being taken seriously. I also received a similar reply on 6/11/26 from Kylie Bromley General Manager and Managing Director, Biogen in the United Kingdom & Ireland. I replied to her directly (below). I hope I have added to the pressure Biogen is under to make a deal to reimburse in the UK.


Sent via email on 31/10/26

Dear Chris,

I am a prominent member of the Friedreich’s Ataxia (FA) community in the UK and am writing to urge you to take action on the availability of Skyclarys here. I am writing on my own behalf, but will be sharing this letter and your response with the FA community and the wider public through social media. While I am very thankful that Biogen has invested in the first treatment for FA, Biogen’s approach to making this drug available has created a storm that is really hurting people with FA and their families.

The problem: Skyclarys simply costs too much. When Biogen bought the developer of Omaveloxolone, Reata, for $7.3Bn in 2023 they overpaid for it. By trying to recover this investment in too short a term, Biogen has set far too high a price for a drug with largely unproven effects. It was introduced of to global markets at the eyewatering price of $370,000 per person, per year; more than 10 times the price that the National Institute for Health and Care Excellence (NICE) is prepared to pay for life-enhancing drugs in the UK. In May 2025, Biogen simply abandoned negotiations with NICE to supply Skyclarys in the UK.

The effects:
• Creating misery in our community: After years of seeing friends and family losing their abilities and dying before their time, the arrival of Skyclarys naturally provoked huge excitement. The failure to distribute the drug in the UK has led to an outpouring of the most heart-breaking feelings amongst our community. Instead of focusing on the present where we can find ways to live with the condition, many are now focused on the future they believe they are missing out on, a future that they feel Skyclarys promises. We feel totally abandoned and the clock of mortality now ticks even louder for us. I fear that Biogen is using our moral outrage to strong-arm public health bodies and insurers around the world into paying for it.

• Unfairly raising expectations: Skyclarys was tested on a relatively small number of young people with FA. Despite being marketed widely by Biogen, there is no evidence for it being effective for adults or those at more advanced stages of the condition. It should be made clear that it is not the ‘magic bullet’ that it is being sold to us as.

• Creating discrimination: Depending on the country they live in, some people with FA are able to access Skyclarys with relative ease whilst those in other countries they cannot. This has opened our community up to direct discrimination on a global stage. I believe that Biogen is playing us all off against each other for profit and wonder if legal action is possible on our part.

T0 find a solution, Biogen must:
• Show some integrity: Biogen must take responsibility for its product, put its hands up and admit that its initial pricing for Skyclarys was incorrect.

• Lower the price of Skyclarys: Review its global marketing strategy for Skyclarys. Dropping at least two zeros from the asking price will place it in a very good position to be considered for distribution in the UK. This lower price will also enable easier access to it in other countries. I know Biogen is a business and has shareholders, but there is more than enough profit in a lower price. After all, this is people’s lives, their futures.

• Negotiate hard: Biogen and NICE must agree to the immediate reimbursement of Skyclarys through the NHS in the UK. I understand that Biogen intervened in Ireland to ease the access problems there. The FA community in the UK campaigned to submit a petition to ask our Government to debate the matter. This debate has been scheduled for 11 January 2027. This problem is not going away and Biogen has the power to resolve it.

You must intervene now to put people before profit. You must do the right thing here. You can still fix this. I look forward to your reply.

Sincerely,

Richard C Brown MBE


Reply received by email on 4/11/26 from Biogen Medical Information Team.

November 4, 2026
Mr. Richard Brown
tristess976@gmail.com

Dear Richard,

Thank you for your email. We recognise that Friedreich’s ataxia is a devastating condition and appreciate the profound burdens it places on people living with the disease and their families.
Biogen was extremely disappointed to have to make the decision to withdraw omaveloxolone from the NICE evaluation process in April 2025.

This decision followed NICE informing Biogen that it would not be willing to conduct a full technology appraisal due to a perceived low likelihood of approval. It would therefore not proceed to a NICE committee meeting where the condition, the treatment and its impact could have been explored thoroughly with input from patients, patient groups and clinicians. We made the decision to withdraw as NICE indicated that they would have terminated the appraisal anyway.

It is Biogen’s intention to resubmit to NICE. We are in dialogue with NICE and the NHS to see how we can find a path forward and remain committed to working collaboratively to secure access to treatment for patients in the UK.
Thank you again for getting in touch with us.
Yours sincerely,
Biogen Medical Information
Interaction#: 00186791


Reply sent by me on 9/11/26

Dear Kylie,

Thanks very much for taking the time to reply to me. The Medical Information Team did get back to me. Unsurprisingly, their reply was very anodyne and did not even relate to any of the points I had had raised. They did not mention forwarding my letter to Christopher Viehbacher for a response. I felt a little better about that when I received your email a few days later.

The Medical Information Team’s reply states: “It is Biogen’s intention to resubmit to NICE. We are in dialogue with NICE and the NHS to see how we can find a path forward and remain committed to working collaboratively to secure access to treatment for patients in the UK.” When that negotiation begins, I assume that you will be a key player and are now aware of the effects on our community of coming to an agreement with NICE. I trust you will do everything you can to lower the price of Skyclarys to make this happen.

Kind regards,

Richard C Brown MBE


Comments

4 responses to “An open letter to Christopher A. Viehbacher, CEO of Biogen.”

  1. Sarah Officer Avatar
    Sarah Officer

    Cmon Biogen out FA patients here in UK are being left behind 💔 we dont have time pls let us access skyclarys omaveloxelone 🙏

    Like

  2. Conor McQuillan Avatar
    Conor McQuillan

    I think Biogen should start worrying about how many people with FA will turn up at their next AGM

    Like

    1. richardcbr0wn Avatar

      I did mention the possibility of legal action against Biogen for opening the UK population up to discrimination.

      Like

  3. Being Heumann review – A joyful and empowering true story – World According to Me: Avatar

    […] An open letter to Christopher A. Viehbacher, CEO of Biogen. […]

    Like

Leave a Reply